Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is down 10% to $5.63. This may have been driven by profit-taking from some investors following a very strong gain last week. Investors were buying the respiratory imaging technology company's shares after it made a big announcement. 4DMedical revealed that its CT:VQ technology has been deployed at the Mayo Clinic in the United States. The company's managing director and CEO, Andreas Fouras, commented: "Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ."

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 3.5% to 14 cents. Although this semiconductor company announced a licensing agreement today, the market doesn't appear overly impressed given the customer and the terms. BrainChip has entered into a technology licensing deal with Korea-based semiconductor company EDGEAI for its Akida 2 neuromorphic IP. The company will receive unspecified payments as it provides various deliverables, including IP access, engineering support, and integration services, as well as royalties on product sales. The agreement is global and non-exclusive, meaning EDGEAI is not restricted from working with other technology providers. In addition, it can be terminated by the customer without cause on one month's notice.

Catapult Sports Ltd (ASX: CAT)

The Catapult Sports share price is down 14% to $2.92. This follows the release of the sports technology company's analyst day presentation. Catapult revealed bold growth ambitions, targeting a rise in average annual contract value (ACV) per pro team from US$20,000 to between US$100,000 and US$150,000. However, this will depend on successful upselling to existing teams and launching additional products.

Star Entertainment Group Ltd (ASX: SGR)

The Star Entertainment share price is down 2% to 12.25 cents. This morning, this casino and resorts operator revealed that it has entered into a binding commitment letter with funds associated with WhiteHawk Capital Partners. This is in relation to a refinancing of its debt. It notes that the annual interest rate based on the term SOFR plus a margin that is materially consistent with its recent facility agreements.

The post Why 4DMedical, Brainchip, Catapult, and Star Entertainment shares are falling today appeared first on The Motley Fool Australia.

At the time of writing, the ASX tech stock is down 3.5% to 14 cents.

Why are Brainchip shares falling today?

The company's shares are falling today despite the release of an announcement revealing a long-awaited licensing agreement.

According to the release, BrainChip has entered into a technology licensing deal with Korea-based semiconductor company EDGEAI for its Akida 2 neuromorphic IP.

The agreement will see BrainChip provide access to its technology, along with integration support and development tools, to assist EDGEAI in incorporating Akida into its future products.

What is it worth?

The company hasn't been able to place a dollar figure on the estimated value of the agreement.

It notes the commercial structure of the agreement is tied to the delivery of technical milestones.

BrainChip will receive unspecified payments as it provides various deliverables, including IP access, engineering support, and integration services.

In addition, the company is eligible to receive royalties based on future product sales from EDGEAI that incorporate its technology. These royalties would only be payable once commercial shipments commence.

Furthermore, any potential royalty stream will be dependent on the success of EDGEAI's products in the market, which is a very large unknown. This is particularly the case given that EDGEAI isn't a proven name in the semiconductor industry.

In fact, rather embarrassingly, EDGEAI's website has gone offline today after exceeding its traffic quota.

Flexible terms

It is also worth highlighting that the agreement is global and non-exclusive, meaning EDGEAI is not restricted from working with other technology providers.

In addition, the licence remains in place only while EDGEAI continues to use the Akida IP and can be terminated by the customer without cause on one month's notice.

Brainchip's CEO, Sean Hehir, said:

We are excited to partner with EDGEAI as they bring their next generation AI solutions to market. This agreement reflects the growing global demand for neuromorphic computing and the unique advantages delivered by our Akida technology. Together, we are enabling smarter, more efficient edge devices that can operate with exceptionally low power while supporting sophisticated on device intelligence.

Foolish takeaway

While today's announcement represents progress in commercialising its technology, the financial contribution from the deal remains uncertain at this stage.

With milestone-based payments and royalties dependent on future product success, the extent to which this agreement translates into meaningful revenue will become clearer over time.

The post What's going on with BrainChip shares today? appeared first on The Motley Fool Australia.

This sees shares in the S&P/ASX 300 Index (ASX: XKO) artificial intelligence (AI) stock down about 43% over the past 12 months.

Nuix Ltd (ASX: NXL) shares have had an even tougher year.

Shares in the ASX 300 investigative analytics and intelligence software provider are down 1% at the time of writing, changing hands for $1.53 each. This puts the Nuix share price down 53.5% over 12 months.

For some context, the ASX 300 has gained 9.9% since this time last year.

And if Peak Asset Management's Niv Dagan has it right, Nuix and Brainchip shares could have further to fall (courtesy of The Bull).

Time to sell Brainchip shares?

"Brainchip is a commercial producer of neuromorphic artificial intelligence (AI)," said Dagan, who has a sell recommendation on Brainchip shares.

If you're not familiar with what that means, the company's neuromorphic processor, Akida, is intended to mimic the human brain and keep machine learning local to the chip, independent of the cloud.

"The company operates across Australia, the US and Europe and had a market capitalisation of about $349.17 million during trading on March 12," Dagan said.

Explaining his sell recommendation, Dagan said:

The broader AI hardware landscape is increasingly dominated by big players, such as Nvidia. The AI sector is intensively competitive. The company substantially lifted revenue in full year 2025 but reported a loss from continuing operations after tax.

Full-year revenue of US$1.9 million was up 374% from 2024. The loss from continuing operations came in at US$20.4 million.

"Brainchip shares have fallen from 24.5 cents on October 9, 2025, to trade at 14 cents on March 12. Other stocks appeal more at this stage of the cycle," Dagan concluded.

Also on the selling block

Apart from Brainchip shares, Dagan also recommends selling Nuix.

"Nuix is an investigative analytics software provider," he said. "It enables customers to process and search large data sets of unstructured information, including emails, documents and communications records."

Despite the sizeable one-year losses, Nuix shares are up 12.1% since the company reported its half-year results on 23 February.

Which could make today a good day to think about taking some profits, according to Dagan. He noted:

The company earns most of its revenue from licence and maintenance fees. Revenue of $121.2 million in the first half of fiscal year 2026 was up 15.2% on the prior corresponding period. Annualised contract value of $234.4 million was up 8.4%.

Investors may want to consider taking a profit as we believe gains are priced in following the half year result. We see limited scope for upside amid increasing competition.

The post Sell alert! Why this expert is calling time on Nuix and Brainchip shares appeared first on The Motley Fool Australia.

Well, if you are, let's see what analysts are saying about the popular shares in this article, courtesy of The Bull.

Are they buys, holds, or sells? Let's find out:

Brainchip Holdings Ltd (ASX: BRN)

The team at Peak Asset Management has named this struggling semiconductor company as a sell this week.

It highlights that the small cap is battling against AI giants like Nvidia (NASDAQ: NVDA) in an intensively competitive sector. It said:

BrainChip is a commercial producer of neuromorphic artificial intelligence (AI). The company operates across Australia, the US and Europe and had a market capitalisation of about $A349.17 million during trading on March 12. The broader AI hardware landscape is increasingly dominated by big players, such as Nvidia.

The AI sector is intensively competitive. The company substantially lifted revenue in full year 2025, but reported a loss from continuing operations after tax. The shares have fallen from 24.5 cents on October 9, 2025 to trade at 14 cents on March 12. Other stocks appeal more at this stage of the cycle.

CAR Group Limited (ASX: CAR)

Over at Baker Young, its analysts are positive on this auto listings company.

It highlights that its shares have fallen heavily recently amid AI disruption concerns. However, the broker believes this has created a buying opportunity and has named it as a buy this week. It said:

This online automotive marketplace operator posted stronger-than-expected first half results for 2026. It grew revenue by 13 per cent and reported EBITDA by 11 per cent. Recent sector-wide selling driven largely by concerns around potential artificial intelligence (AI) disruption has weighed on valuations. However, we believe CAR's trusted brands, established distribution network and strong dealer relationships position it well to integrate AI tools into its services rather than be disrupted by them.

Over time, AI could enhance listing quality, pricing transparency and advertising effectiveness across its platforms. Given the company's strong market position, attractive margins and long runway for digital automotive marketplace growth across several geographies, we view recent price weakness as an opportunity to accumulate a high quality technology-enabled marketplace at a more reasonable valuation.

Endeavour Group Ltd (ASX: EDV)

Finally, Baker Young has been looking at drinks giant Endeavour. It felt that the Dan Murphy's owner delivered a solid half-year result last month.

However, it isn't enough for a buy rating just yet. The broker has put a hold rating on its shares instead. It said:

The drinks and hotels operator delivered solid first half results for fiscal year 2026. Hotel sales increased by 4.4 per cent and total retail sales increased by 0.2 per cent. Hotel sales growth in the first seven weeks of the second half of fiscal year 2026 was up 4.5 per cent followed by 1.3 per cent for retail sales.

The company is investing heavily in price competition to support volumes, which will likely pressure margins in the near term. While it may be too early to call a full recovery, we believe risks are broadly balanced and we're comfortable maintaining our position ahead of the strategic update.

The post Buy, hold, sell: Brainchip, CAR Group, and Endeavour shares appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 9.5% to 14 cents. This struggling semiconductor company's shares have come under pressure again since the release of its full-year results last week. It was another disappointing release, with Brainchip reporting revenue of US$1.9 million and a massive operating loss of US$21.7 million for the 12 months. Investors appear to be doubting whether Brainchip will ever gain any meaningful commercial traction given how it is competing with companies that have R&D budgets that dwarf its own.

Fortescue Ltd (ASX: FMG)

The Fortescue share price is down 4% to $20.24. This has been driven by the iron ore giant's shares going ex-dividend this morning for its latest payout. Last month, Fortescue released its half-year results and reported a 23% increase in net profit after tax to US$1.9 billion. This allowed the Fortescue board to increase its fully franked interim dividend by 24% to 62 Australian cents per share. Eligible shareholders can now look forward to receiving this dividend later this month on 30 March.

Qantas Airways Ltd (ASX: QAN)

The Qantas share price is down 6% to $9.36. This appears to have been driven by war in the Middle East after the US struck Iran. And with Iran retaliating against its neighbours, this could impact travel demand in the near term. In addition, it is expected to cause oil prices to spike. And given how fuel is an airline's biggest operating cost, this could have a negative impact on its second-half earnings. A number of other ASX travel stocks are trading lower today in response to the news.

Westpac Banking Corp (ASX: WBC)

The Westpac share price is down 3% to $41.22. This is despite there being no news out of Australia's oldest bank. However, it is worth noting that all of the big four banks are trading lower today. This could have been driven by profit-taking from some investors after strong gains were recorded in the sector in February. This has seen the S&P/ASX 200 Financials index tumble by 2.7% on Monday afternoon.

The post Why Brainchip, Fortescue, Qantas, and Westpac shares are dropping today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Bapcor Ltd (ASX: BAP)

The Bapcor share price is down 47% to 90.5 cents. This morning, the auto parts retailer's shares returned from a trading halt after completing the institutional component of its $200 million equity raising. The struggling retailer raised $157 million from institutional investors at a 65% discount of 60 cents per new share. The company's new CEO, Chris Wilesmith, said: "Raising $200M of equity will improve our financial flexibility and business resilience in the current market conditions and provide headroom to focus on 'getting the engine running' to improve our operating performance and execution." The retail component of the entitlement offer, which is fully underwritten, is expected to raise a further $43 million.

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 7% to 13 cents. Investors have been selling the embattled semiconductor company's shares after it released its full-year results. Brainchip reported revenue of US$1.9 million for the 12 months and a massive operating loss of US$21.7 million. Brainchip's founder and director, Peter van der Made, said: "We recognize that the ultimate measure of our strategy is commercial success. The foundations we continue to build in 2026 – from silicon validation to reference designs – are the essential drivers of our commercial success, and we are executing this strategy with full conviction. We remain deeply committed to the success of this Company and look forward to your continued engagement."

Coles Group Ltd (ASX: COL)

The Coles share price is down 9% to $20.20. This follows the release of the supermarket giant's half-year results. For the 27 weeks ended 4 January 2026, Coles reported a 2.5% lift in sales revenue to $23.6 billion and a 12.5% jump in profit after tax (excluding significant items) to $676 million. This was short of expectations. For example, Morgans was expecting a 3.5% increase in revenue and a 16.5% jump in underlying net profit after tax to $699 million.

Harvey Norman Holdings Ltd (ASX: HVN)

The Harvey Norman share price is down 8% to $5.81. This morning, this retail giant released its half-year results and reported a 6.9% increase in sales revenue to $5.16 billion and a 16.5% lift in profit after tax to $321.9 million. While this looks strong on paper, it was a touch short of consensus expectations.

The post Why Bapcor, Brainchip, Coles, and Harvey Norman shares are dropping today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Bougainville Copper Ltd (ASX: BOC)

The Bougainville Copper share price is down 3.5% to 79 cents. Investors have been selling this copper stock after it announced the termination of a strategic partnering process with the president of the Autonomous Bougainville Government. This is in relation to the selection of an international mining partner for the redevelopment of the Panguna Mine.

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down a further 3.5% to 13.5 cents. This semiconductor company's shares have come under significant pressure since the release of another disappointing quarterly update. Brainchip reported cash receipts of just US$0.4 million for the three months ended 31 December, despite entering the commercialisation stage a few years ago. Investors appear to be doubting whether Brainchip realistically has any chance of ever competing with chip developers that spend billions on research and development each year.

Challenger Ltd (ASX: CGF)

The Challenger share price is down 3.5% to $8.60. This follows news that the annuities company is in advanced talks to jointly acquire Pepper Money Ltd (ASX: PPM) with Pepper Group ANZ HoldCo. Challenger believes the potential acquisition would provide long-term access to fixed income assets and support its strategic growth plans. If completed, Challenger would hold no more than 25% of total Pepper Money shares. It seems that the market isn't overly keen on the deal.

HMC Capital Ltd (ASX: HMC)

The HMC Capital share price is down almost 5% to $3.73. This morning, Morgan Stanley retained its equal-weight rating and $3.85 price target on the investment company's shares. Its analysts think that HMC Capital's shares are fair valued at current levels. Though, it is worth noting that other brokers see more value in the company's shares. For example, last month Morgans put a buy rating and $6.60 price target on its shares. Based on its current share price, this implies potential upside of approximately 75% for investors over the next 12 months. Time will tell which broker has made the right call on this one.

The post Why Bougainville Copper, Brainchip, Challenger, and HMC Capital shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 2% to 15.2 cents. This semiconductor company's shares have been under heavy selling pressure since the release of another disappointing quarterly update. Despite entering the commercialisation stage a few years ago, Brainchip revealed cash receipts of just US$0.4 million for the three months ended 31 December. Given that its market capitalisation is still $350 million, it wouldn't be surprising if the selling continues if there's no meaningful improvement in its sales.

Credit Corp Group Ltd (ASX: CCP)

The Credit Corp share price is down over 15% to $12.07. Investors have been selling this debt collector's shares following the release of its half-year results. Credit Corp posted a 4% increase in revenue to $283.6 million and flat net profit after tax of $44.1 million. Looking ahead, management believes it can still achieve its net profit after tax guidance range of $100 million to $110 million. Investors don't appear confident it will get there.

Graincorp Ltd (ASX: GNC)

The Graincorp share price is down 3% to $6.00. This may have been driven by a broker note out of Macquarie Group Ltd (ASX: MQG). This morning, the broker downgraded the grain exporter's shares to a neutral rating (from outperform) with a reduced price target of $6.60 (from $8.30). Macquarie appears concerned that margins could remain under pressure in the near term, which could weigh on its earnings growth.

Neuren Pharmaceuticals Ltd (ASX: NEU)

The Neuren Pharmaceuticals share price is down 12% to $14.25. This morning, Neuren Pharmaceuticals revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative trend vote on its marketing authorisation application for trofinetide in the European market. Neuren's CEO, Jon Pilcher, commented: "Given the totality of experience with trofinetide in clinical trials and real world use over many years, this negative trend vote is frustrating for us and the Rett syndrome community in the EU. We fully support Acadia's intention to seek re-examination of the CHMP opinion in February, if necessary."

The post Why Brainchip, Credit Corp, Graincorp, and Neuren shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 6% to 15.5 cents. Investors have been selling this semiconductor company's shares following the release of another disappointing quarterly update. Brainchip recorded cash receipts of just US$0.4 million for the three months ended 31 December. That's despite it entering the commercialisation stage a few years ago. And with its market capitalisation now at $350 million, it seems that some investors are finally recognising that this premium valuation is undeserved.

Galan Lithium Ltd (ASX: GLN)

The Galan Lithium share price is down 13% to 40.7 cents. This morning, this lithium developer announced that it has received firm commitments from institutional and sophisticated investors for a $40 million placement at a discount of 41 cents per new share. The proceeds will be used to complete phase one construction activities, expand phase one production capacity from 4 ktpa LCE to 5.2 ktpa LCE, undertake exploration activities at Greenbushes South, and for working capital purposes. The company's managing director, Juan Pablo Vargas de la Vega, commented: "An accelerated recovery in lithium prices has provided Galan with an opportunity to expand HMW Phase 1 production capacity by 30%."

Iluka Resources Ltd (ASX: ILU)

The Iluka Resources share price is down 13.5% to $5.58. Investors have been selling this mineral sands company's shares after it revealed that it would recognise $565 million in impairment charges in its upcoming first-half results. It advised: "The suspension [of the Cataby mine] was enacted given subdued demand for mineral sands and their associated downstream products, particularly pigment. The persistence of these demand conditions has impacted price expectations in the nearer term."

Ora Banda Mining Ltd (ASX: OBM)

The Ora Banda Mining share price is down 13% to $1.44. This morning, this gold miner released its quarterly update and revealed record gold production. However, looking further ahead, management is now guiding to the low end of its production guidance range and has increased its cost guidance meaningfully. Its FY 2026 all-in sustaining cost (AISC) is now expected to be $3,250 per ounce to $3,350 per ounce from $2,800 to $2,900 per ounce.

The post Why Brainchip, Galan Lithium, Iluka, and Ora Banda shares are tumbling today appeared first on The Motley Fool Australia.

In morning trade, the struggling semiconductor company's shares are down 3% to 16 cents.

This leaves them trading within a whisker of a multi-year low.

Why are Brainchip shares sinking?

Investors have been hitting the sell button again today after the company released yet another dismal quarterly update.

According to the release, the company recorded a cash inflow of just US$0.4 million for the three months ended 31 December.

That's an average of approximately US$130,000 a month for a company that entered the commercialisation stage a few years ago and has a market capitalisation over $360 million.

Unsurprisingly given its tiny cash inflows, Brainchip continues to burn cash. It revealed payments to suppliers and employees of US$4.3 million for the three months. Though, one small positive was that this was lower than the prior quarter when it spent US$5.2 million.

At the end of the quarter, the company had a cash balance of US$31.7 million. This is up from US$13.9 million in the prior quarter due to the successful completion of a US$22.8 million fully underwritten institutional placement in November.

Management notes that this capital raising was done to support the commercialisation of the Akida neuromorphic technology platform and the development of next-generation edge AI products. Though, time will tell if these funds accomplish anything other than paying the salaries of its leaders.

What else did it announce?

Brainchip also provided the market with an update on what it has been working on during the quarter.

This includes a strategic partnership with Blue Ridge Envisioneering, which is a Parsons (NYSE: PSN) entity. It notes that BRE is a Virginia-based innovator delivering next-generation solutions to the defence and intelligence sectors.

The terms of the agreement include an initial order of 10,000 chips, supporting the deployment of edge-AI systems that maintain full performance without cloud connectivity. It said:

Parsons will integrate BrainChip's Akida neuromorphic processors into its mission-ready platforms to enhance adaptive performance in constrained and dynamic defence environments. The agreed supply framework with Parsons includes committed volumes for manufacturing scale, continuity-of-supply provisions, and tiered pricing for high-volume deployment.

It also advised that it received an initial order for 1,200 AKD1500 chips from Nex Novus for use in its Neuromorphyx Neuro Blocks product. Management believes AKD1500 will accelerate an MCU supporting neuromorphic evaluation of multi-sensor data. And while it concedes that the order size is minor, it feels it represents further market demand for the AKD1500.

Time will tell if this leads to more orders, but I wouldn't hold my breath.

The post Why are Brainchip shares sinking today? appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Alliance Aviation Services Ltd (ASX: AQZ)

The Alliance Aviation Services share price is down 7% to $1.35. This appears to have been driven by a couple of broker notes out of Morgans and Ord Minnett. Both brokers have downgraded this aviation services company's shares to a hold rating from buy this morning. Morgans said: "AQZ has released a disappointing trading update with FY26 NPBT expected to be ~40% below our previous forecast and consensus. The stock is now in a very tough spot – ex-growth and earnings going backwards, management changes, accounting issues, highly levered balance sheet, poor cashflow generation and deteriorating returns on capital. With AQZ's strategic review ongoing, we are hopeful of possible corporate activity (but not guaranteed). Despite the poor earnings performance, the stock continues to trade well below NTA of ~A$2.90 and aviation assets are liquid and remain in strong demand. We downgrade our rating to HOLD."

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down almost 7% to 18.2 cents. This morning, this struggling semiconductor company announced a fully underwritten $35 million placement to professional and sophisticated investors. These funds are being raised at a 10.3% discount of 17.5 cents per new share. Brainchip's CEO, Sean Hehir, said: "This capital raise positions BrainChip to accelerate our leadership in edge AI and neuromorphic computing. With Akida 2.0 and our expanding product portfolio, we are unlocking new commercial opportunities in high-growth sectors and driving scalable innovation. Investor support enables us to execute with confidence and deliver long-term value through transformative, on-device intelligence."

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is down almost 4% to $4.72. This has been driven by news that the pharmaceutical company has received a notice of intention to appeal by Cosette Pharmaceuticals. This relates to last month's judgement in the Supreme Court of New South Wales, which found in favour of Mayne Pharma and dismissed Cosette's request to cancel its takeover offer. Mayne Pharma notes that the notice of intention does not include any reasons for Cosette's intention to appeal.

Perpetual Credit Income Trust (ASX: PCI)

The Perpetual Credit Income Trust share price is down over 6% to $1.13. This has been driven by news that the income trust intends to raise up to ~$267 million via a 1 for 2 pro-rata non-renounceable entitlement offer to eligible unitholders and a shortfall offer. The proceeds are intended to be used to enable the investment manager to actively pursue additional investments in accordance with its current investment strategy and objective.

The post Why Alliance Aviation, Brainchip, Mayne Pharma, and Perpetual Credit shares are sinking today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Australian Strategic Materials Ltd (ASX: ASM)

The Australian Strategic Materials share price is down 17% to $1.34. This morning, the integrated materials business revealed that it has received firm commitments for an institutional placement to raise approximately $55 million at a sizeable discount of $1.20 per new share. Managing director, Rowena Smith, said: "We are now fully funded to execute our Phase 2 ramp-up plan at the Korean Metals Plant (KMP). Completion of Phase 2 expansion activities will double our existing NdFeB alloy capacity to 3,600 tonnes per annum. This increased capacity will enable us to service the growing demand of our existing customers and the increasing number of enquiries we have received in recent months."

Bapcor Ltd (ASX: BAP)

The Bapcor share price is down 15% to $2.69. Investors have been selling this auto parts retailer's shares after it released its guidance for FY 2026. Management revealed that first half underlying profit is expected to be in the range of $14 million to $18 million. This is down sharply from $45.5 million in the prior corresponding period. On a statutory basis, things will be even worse, with a profit of $3 million to $7 million expected. And this doesn't include any potential impairments associated with the New Zealand segment. A stronger second half is expected, with management guiding to full year statutory profit in the range of $40 million to $50 million.

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 2.5% to 20.5 cents. This morning, this struggling semiconductor company appeared to change its business model out of the blue once again. After hyping up its potential to sell IP, Brainchip has now announced a shift back to trying to sell chips. This will see Brainchip tape out AKD1500 chip with its foundry partner. Though, the first units are not expected to be available until the third quarter of 2026. Brainchip CEO, Sean Hehir, said: "We are confident that this strategic step will position BrainChip for commercial success."

Deep Yellow Ltd (ASX: DYL)

The Deep Yellow share price is down 16% to $1.95. This has been driven by news that the uranium producer's CEO is stepping down after almost a decade at the company. Deep Yellow's chief financial officer (CFO), Craig Barnes, will lead the organisation as acting CEO until a permanent appointment is made. The company stated: "John leaves an incredible legacy at Deep Yellow having built one of the most experienced uranium mining leadership teams in the industry."

The post Why Australian Strategic Materials, Bapcor, Brainchip, and Deep Yellow shares are dropping today appeared first on The Motley Fool Australia.

But in reality, you don't need to chase risky stocks to build serious wealth on the ASX.

By taking a patient, disciplined approach, investors can let time and quality do most of the heavy lifting. Here's how.

Focus on quality ASX shares

The simplest way to double your portfolio is to own high-quality assets and give them time to grow. On the ASX, this can mean buying into reliable blue chips like Goodman Group (ASX: GMG) or global leaders such as ResMed Inc (ASX: RMD), which both have long track records of compounding returns.

Another approach is through exchange traded funds (ETFs). Funds like the iShares S&P 500 ETF (ASX: IVV) or the Betashares Nasdaq 100 ETF (ASX: NDQ) give you instant exposure to many of the world's best stocks, such as Microsoft (NASDAQ: MSFT) and Apple (NASDAQ: AAPL), without having to pick winners yourself.

The power of compounding

You don't need to double your money in one big leap. At a 10% average annual return, which is roughly in line with long-term equity market averages, your portfolio would double in just over 7 years.

That means $20,000 invested today could become $40,000 within a decade.

After which, as compounding accelerates your wealth creation, your ASX share portfolio would become worth $60,000 in approximately 12 years, $80,000 in approximately 15 years, and then $100,000 in approximately 17 years.

Reinvest dividends

One of the advantages of investing in Australia is the high dividend culture.

ASX shares like Telstra Group Ltd (ASX: TLS) and Harvey Norman Holdings Ltd (ASX: HVN) provide reliable, fully franked dividends that you can reinvest to supercharge compounding.

Over time, reinvested dividends can account for a good portion of total returns.

Avoid the traps

The temptation to chase speculative miners or unproven tech startups like Brainchip Holdings Ltd (ASX: BRN) can be strong, especially when markets are booming. But the risk of permanent capital loss is high.

By sticking to profitable businesses with competitive advantages and robust balance sheets, you reduce the chance of painful drawdowns that can set back your journey to doubling your portfolio.

Foolish takeaway

You don't need luck or risky punts to double your portfolio. What you need is time, discipline, and exposure to quality ASX shares and ETFs.

By focusing on businesses with strong fundamentals and reinvesting dividends along the way, you can steadily grow your wealth — and double your portfolio — without taking on unnecessary risk.

The post How to double your ASX share portfolio without chasing risky stocks appeared first on The Motley Fool Australia.

Here's a simple framework — with some real ASX examples — to help guide those decisions.

When to buy

One of the best times to buy is when a quality business is temporarily out of favour, trading at a discount to its long-term potential.

Take Treasury Wine Estates Ltd (ASX: TWE). Market worries over global demand have weighed on its share price, but the company still owns premium brands and has been growing its footprint in key markets like China and the U.S.

Similarly, Woolworths Group Ltd (ASX: WOW) shares are down in the dumps right now. It isn't a flashy stock, but it is a defensive giant with steady cash flow and dominant market share in Australian supermarkets.

It is also worth remembering that you don't always need to wait for a bargain.

Buying high-quality ASX shares at fair prices can be just as rewarding if you plan to hold for the long term. ResMed Inc (ASX: RMD), with its global leadership in sleep and respiratory care, and Temple & Webster Group Ltd (ASX: TPW), with its fast-growing online retail platform, are examples of stocks that may not look cheap but have significant growth potential that justifies their valuations.

When to hold

Holding is often underrated, yet it is the stage where compounding works its magic. If the company is still growing strongly and your original thesis is intact, there's no need to sell.

For example, Pro Medicus Ltd (ASX: PME) has been delivering consistent revenue growth through its cutting-edge medical imaging software. With long-term contracts and global demand rising, it is a classic compounding story worth holding.

Another one is TechnologyOne Ltd (ASX: TNE). As one of Australia's most successful software-as-a-service companies, it has built a reputation for sticky customers and recurring revenues. Long-term holders have been rewarded handsomely, and the growth runway remains strong.

When to sell

Selling should be the exception, not the rule — but sometimes it is the smart move.

Consider Commonwealth Bank of Australia (ASX: CBA). It is a high-quality bank, but it is also widely regarded as one of the most expensive bank stocks in the world. If the valuation becomes detached from realistic earnings growth, taking profits might make sense.

On the other end of the spectrum is Brainchip Ltd (ASX: BRN). Despite plenty of hype on social media around its AI technology, the company has almost no sales, faces huge competition, and has been criticised for poor management. When a speculative stock fails to deliver, investors may be better off cutting their losses.

Foolish takeaway

The art of knowing when to buy, hold, or sell comes down to discipline. Look for quality ASX shares at good prices, hold onto long-term compounders, and don't be afraid to walk away from overvalued or speculative names.

By following this framework, you can avoid knee-jerk reactions and let your investments work harder for you over the years.

The post How to know when to buy, hold, or sell ASX shares appeared first on The Motley Fool Australia.

Unlike dividend stocks, which focus on income today, growth companies reinvest their profits into expanding their businesses — compounding earnings and, in many cases, delivering outsized returns over time.

Here's why ASX growth shares could make you rich, and a few examples that show their potential.

The power of compounding

The magic of growth investing lies in compounding. When a company expands its revenue and profits year after year, shareholders benefit not only from higher earnings but also from the market rewarding that success with a higher share price.

Some of the ASX's strongest performers over the past decade have turned a relatively small initial investment into a significant sum simply by holding on through the ups and downs.

Examples of ASX growth share leaders

CSL Ltd (ASX: CSL) is the gold standard of ASX growth shares. From its origins as a government laboratory, it is now a global biotechnology leader. A long track record of innovation in plasma therapies and vaccines has made CSL one of the best long-term compounders on the ASX.

WiseTech Global Ltd (ASX: WTC) has transformed the logistics software industry. Its CargoWise platform has over 17,000 customers across 193 countries and is generating strong recurring revenue model. Overall, WiseTech shows how a high-quality technology business can scale globally from an Australian base.

Xero Ltd (ASX: XRO) is another standout. From humble beginnings in New Zealand, Xero has grown into one of the world's leading cloud accounting platforms for small businesses. With millions of subscribers worldwide and a long runway for digital adoption, Xero continues to demonstrate what global expansion can deliver.

Where to focus

Not every ASX growth share will make you rich. Chasing speculative names can lead to disappointment. Just ask buyers of Brainchip Holdings Ltd (ASX: BRN) shares. The key is to focus on quality — companies with strong balance sheets, durable competitive advantages, and expanding addressable markets.

By concentrating on businesses that can sustain growth over many years, investors give themselves the best chance of capturing compounding at work.

Foolish takeaway

ASX growth shares like CSL, WiseTech, and Xero highlight the incredible wealth-building potential of backing innovative, high-quality companies for the long haul.

They won't all rise in a straight line, and there will be volatility along the way. But for investors who stay the course, growth shares could be the very thing that makes you rich over time.

The post How ASX growth shares could make you rich appeared first on The Motley Fool Australia.

Time allows strong businesses to compound earnings, reinvest profits, and reward patient shareholders — often in ways that short-term traders miss.

But how do you find those rare ASX growth shares with true staying power? Here are a few key things to look for.

Look for ASX shares with a long growth runway

The best long-term investments are businesses operating in growing industries. These could include technology, healthcare, cloud computing, logistics, or clean energy — sectors with structural tailwinds that are likely to get stronger over time.

For example, WiseTech Global Ltd (ASX: WTC) has benefited from the ongoing digitisation of global logistics, while ResMed Inc (ASX: RMD) has grown steadily with the rising demand for sleep and respiratory health solutions.

Prioritise strong business models and competitive advantages

A great product is not enough. The best ASX growth shares typically have durable competitive advantages, such as proprietary technology, strong branding, scale, or network effects.

Xero Ltd (ASX: XRO), for instance, has built deep customer loyalty in cloud accounting software, making it difficult for competitors to win market share. Similarly, CSL Ltd (ASX: CSL) has high barriers to entry in the biotech space thanks to its manufacturing scale and global plasma collection network.

Focus on consistent earnings growth and reinvestment

Quality ASX growth shares don't just grow once — they grow again and again. Look for businesses with a track record of earnings growth, high reinvestment rates, and strong returns on capital.

This is where long-term compounding comes in. Even moderate annual growth, compounded over a decade, can lead to impressive returns.

Avoid hype and short-term trends

It is easy to get caught up in market excitement, but successful long-term investing often comes down to avoiding mistakes. Be cautious with speculative stocks like Brainchip Holdings Ltd (ASX: BRN) with unproven business models, or companies with unclear profitability paths.

Instead, stick to high-quality businesses that are already profitable (or at least close to it), with real products, customers, and scale.

Foolish takeaway

Finding great ASX growth shares is part research, part patience.

Focus on businesses with clear competitive advantages, strong industry tailwinds, and disciplined reinvestment strategies — and give them time to work. Holding for 10+ years can feel boring at times, but it is one of the most effective ways to build lasting wealth on the ASX.

The post How to find quality ASX growth shares to hold for 10+ years appeared first on The Motley Fool Australia.

And by focusing on high-quality businesses or diversified ETFs, you can give yourself a solid chance to hit that six-figure milestone.

Hitting $100,000 with ASX shares

The Australian share market has delivered an average total return of approximately 10% over the long term. And while there are no guarantees in investing, it wouldn't be at all surprising if this trend continues in the future.

Let's assume that it does. If you started with $10,000 and earned an average annual return of 10%, it would take just over 24 years to grow your investment to $100,000.

But there's a faster route.

Making regular contributions

The above example assumes that you put $10,000 into ASX shares and then nothing further (other than reinvested dividends).

But that's not the way to fully take advantage of the power of compounding. Making regular contributions is the best way to feel its force.

What if you committed to adding $300 per month to your investment?

In that case, assuming the same 10% annual return and $10,000 starter balance, you could grow your portfolio to $100,000 in just over 11 years.

The key is consistency. Sticking to a regular investing plan — even when markets become volatile — can be more powerful than trying to time your entry perfectly.

Where to invest on the ASX?

There are a lot of options for investors on the Australian share market. But the main thing is that you focus on quality.

The cream always rises to top, they say. So, you only want the crème de la crème in your portfolio.

This might mean buying high quality ASX shares like CSL Ltd (ASX: CSL), Goodman Group (ASX: GMG), Pro Medicus Ltd (ASX: PME), or ResMed Inc. (ASX: RMD).

Alternatively, you could look at high-quality ASX ETFs like the iShares S&P 500 ETF (ASX: IVV) and Betashares Nasdaq 100 ETF (ASX: NDQ). They provide investors with easy access to the best companies on Wall Street.

Don't destroy wealth

As mentioned above, investors want to focus on quality and not chase hot stocks with poor fundamentals.

Countless investors have destroyed significant wealth betting on speculative stocks that promise the world and deliver nothing like Brainchip Ltd (ASX: BRN).

If you lose 50% on an investment, you need to then achieve a 100% return to just get square. This demonstrates why losing money can set you back significantly.

So, by avoiding speculation and focusing on quality you will be setting yourself up as best as possible for success.

Foolish takeaway

Turning $10,000 into $100,000 won't happen overnight — but it is possible with discipline, time, and a long-term mindset.

If you're consistent with your contributions, stay invested through market cycles, and back quality investments, you could be surprised at how far your money can grow on the ASX.

The post How you could turn $10k into $100k with ASX shares appeared first on The Motley Fool Australia.

It's no surprise, then, that interest in AI stocks on Australian share markets has surged.

A recent AUSIEX report reveals a 43% increase in trade volumes and a 41% increase in traded value year over year.

And some ASX-listed stocks are more in favour than others.

Appen Ltd (ASX: APX) was the most traded artificial intelligence stock on the ASX from April 1 to June 15. 

This was followed by NextDC Ltd (ASX: NXT) and then BrainChip Holdings Ltd (ASX: BRN).

Here is the full list of the 10 most traded AI stocks in Q2 of the 2025 calendar year, according to AUSIEX data.

Appen

Appen provides data for training AI models, including natural language processing and machine learning systems. 

The company's shares are trading 2.66% higher at $1.16 today, which represents an impressive 136.73% increase over the year to date.

Appen's share price suffered a dramatic 54.68% decrease over 72 hours in late February after the company posted a 14% decrease in revenue in its annual 2024 results. This was mostly due to the termination of its contract with Google. 

The share price dropped to a low of $0.78 in April and has since slowly begun to recover.

BrainChip Holdings 

Brainchip specialises in neuromorphic computing, developing the Akida chip. 

The company's shares are trading 7.9% higher today at $0.205 each. 

For the year, BrainChip's shares are down 4.65% thanks to a 74% spike in late-December. Investor buying rocketed after the company secured a commercial licence agreement with Frontgrade Gaisler, a Swedish leader in radiation-hardened microprocessors for space applications.

Dicker Data Ltd (ASX: DDR) 

Dicker Data distributes IT hardware and software, including AI solutions, to resellers. 

The company's shares are trading 0.38% lower today at $7.97 a piece.

Over the year, Dicker Data's share price has slowly corrected downwards and is 18.76% lower to date. The trend follows the company's half-year results announcement in August last year.

FBR Ltd (ASX: FBR) 

FBR, or Fastbrick Robotics, develops robotic systems for construction, integrating AI for autonomous bricklaying. 

The company's shares are trading hands 8.33% lower today at $0.0055 each. The share price has fallen 85.9% since February this year after the company released a disappointing update.

The current trading price represents a 78% decline over the year. 

Macquarie Technology Group Ltd (ASX: MAQ) 

Macquarie Technology offers data centre and cloud services that facilitate AI workloads. 

The company's shares are trading 1.28% today at $65.06. Over the year, the share price is down 29.96%.

Megaport Ltd (ASX: MP1) 

Megaport provides network connectivity services that support AI applications requiring high-speed data transfer. 

The company's share price is trading hands at $13.47 today, 0.37% higher. The AI company is benefiting from the AI demand boom this year. The share price has risen 102.2% since January, and is up 14.25% for the year.

The team at Morgans has an accumulate rating and $15.50 price target on its shares.

NextDC 

NextDC operates data centres necessary for AI processing and storage needs. 

The company's share price is trading 0.91% higher today at $14.38. The stock is 18.34% lower over the year after the price plunged in April. But it has since posted a strong and consistent recovery.

Morgans is very bullish on NextDC and sees it as a great way to invest in AI. It has a buy rating and a $18.80 price target on its shares.

Opyl Ltd (ASX: OPL) 

Opyl applies AI to improve clinical trials. 

The company's shares are trading 42.11% higher today at $0.0080. Year-to-date, the stock's price is 35% higher.

Straker Translations Ltd (ASX: STG) 

Straker offers AI-powered language translation services. 

The company's share price is 7.14% higher today at $0.45 per share and is flat over the year. 

Weebit Nano Ltd (ASX: WBT) 

Weebit Nano develops AI-integrated memory solutions.

The company's shares are trading 4.27% higher today at $1.71. Weebit's share price spiked in November last year, and again in December, after the company said it was "well-funded for technical and commercialisation activities". 

Since then, the share price has returned to levels seen before the spikes.

The post 10 most traded AI stocks on the Australian share market in Q2 appeared first on The Motley Fool Australia.

Of course, we can't say for certain what Buffett would buy on the ASX for Berkshire Hathaway (NYSE: BRK.B), but by studying his investment philosophy, we can make a good guess at what kind of Australian shares he might consider if he were building a portfolio here.

So, what exactly would Warren Buffett look for in ASX shares?

Warren Buffett loves moats

Buffett is laser-focused on companies that have a sustainable competitive advantage — what he calls an economic moat. This could come in the form of strong branding, proprietary technology, network effects, or high switching costs that make it hard for customers to leave.

On the ASX, companies like CSL Ltd (ASX: CSL) and Cochlear Ltd (ASX: COH) spring to mind. These are global healthcare leaders with decades of R&D, customer trust, and high barriers to entry. Buffett would likely appreciate their dominance in niche but essential markets.

Strong and predictable cash flows

Warren Buffett doesn't like uncertainty when it comes to profits. He prefers businesses that generate reliable, recurring cash flows — even better if they distribute a portion of those returns to shareholders.

ASX shares like Woolworths Group Ltd (ASX: WOW) and Transurban Group (ASX: TCL) might appeal here. They generate steady income from supermarket and toll road operations — two industries with consistent demand.

High return on equity

Berkshire Hathaway's leader often highlights return on equity (ROE) as a key metric. He wants to see that management is using shareholder capital efficiently and generating attractive returns without excessive debt.

A company like REA Group Ltd (ASX: REA) — the operator of realestate.com.au — may tick this box. It earns high margins, has a dominant position in property classifieds, and has delivered strong returns over the long term.

Simple businesses

Buffett once quipped that "If you don't understand it, don't buy it." He famously avoids businesses he doesn't understand, no matter how exciting they seem. He's drawn to simplicity and predictability.

For example, Brainchip Holdings Ltd (ASX: BRN) has consistently destroyed shareholder wealth in recent years while promising to change the world with its AI technology. Investors that avoided this dud are now richer than those that didn't.

Fair valuations

Warren Buffett is a value investor at heart. While he's happy to pay a fair price for a great business, he doesn't chase hype or overpay for growth. He looks for quality companies trading at sensible valuations relative to their earnings and long-term prospects.

Right now, some high-quality ASX shares are trading at more attractive prices after recent pullbacks — and Buffett may well see that as an opportunity. ASX shares like Treasury Wine Estates Ltd (ASX: TWE) and Accent Group Ltd (ASX: AX1) spring to mind.

Buffett once said:

It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price.

Foolish takeaway

We can't know with certainty what Warren Buffett would buy on the ASX, but his principles are clear: strong businesses with sustainable moats, reliable earnings, high returns on equity, and honest, capable management — all bought at a fair price.

The post What Warren Buffett would look for in ASX shares appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 3.5% to 20.75 cents. This is despite there being no news out of the struggling semiconductor company. Though, it is worth noting that earlier this week the company reported more insider selling.  According to change of director interests notices, Antonio Viana sold 130,000 Brainchip shares for a total of $27,950 and Pia Turcinov sold 175,331 Brainchip shares for a total of $37,696.17.

Findi Ltd (ASX: FND)

The Findi share price is down 9% to $4.59. Investors have been selling this payments company's shares following the release of its full year results. Findi reported a 13.5% increase in revenue to a record of $75.5 million and a 14.4% lift in EBITDA to $31.4 million. The latter was in the middle of its guidance range. Management advised that this reflects the strong performance of the core ATM business and continued growth of FindiPay's merchant network. Judging by the share price reaction, the market was expecting stronger growth from the India-focused company.

Lottery Corporation Ltd (ASX: TLC)

The Lottery Corporation share price is down almost 4% to $5.16. This appears to have been driven by the release of a broker note out of Morgans this morning. According to the note, the broker has downgraded the lotteries company's shares to a hold rating with a trimmed price target of $5.50. Morgans made the move in response to lower jackpot activity. In addition, it highlights that its shares have rallied strongly from recent lows.

REA Group Ltd (ASX: REA)

The REA Group share price is down 2.5% to $240.30. This property listings giant's shares have come under pressure this week after the ACCC launched an investigation. The company stated: "REA confirms that it has received a s155 Notice from the ACCC, requiring REA to provide information regarding certain subscription offerings." It then adds: "REA is committed to providing choice, value and flexibility to its customers and consumers, and remains focussed on delivering products and services that improve the property experience of buyers, sellers and renters. The value that REA provides is underpinned by the 12.3 million people who visited realestate.com.au each month on average in the March quarter, with 6.4 million exclusively using realestate.com.au."

The post Why Brainchip, Findi, Lottery Corp, and REA shares are falling today appeared first on The Motley Fool Australia.